Highlights

Jul 20, 2026 7:55 AM Eastern Daylight Time Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000 Immunomic Therapeutics Announces First Patient Dosed in

Jun 15, 2026 7:55 AM Eastern Daylight Time ITI Announces PMDA Clearance of CTN for a UNITE®-Based Self-Amplifying RNA Treatment for Japanese Red Cedar Allergy Company to Initiate First-in-Human Phase

Jan 20, 2026 12:03 PM Eastern Standard Time Immunomic Therapeutics Announces FDA Clearance of IND Application for a UNITE®-Based Self-Amplifying RNA Vaccine for Triple-Negative Breast Cancer, to Be Studied Alone

Immunomic Therapeutics is proud to be a bronze sponsor for The Alliance for mRNA Medicines (AMM) 1st Annual Meeting. The event will bring together senior executives and top decision-makers in the

Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile Patients showed

Immunomic Therapeutics' article titled, "LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition," has been published in Frontiers

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme -Top-Line Data Expected in the Second Quarter of

Immunomic Therapeutics' Prakash Koodathingal, Director of RNA Therapeutics Development, shares his insight into CQAs for saRNA for GEN magazine's "Expansion of the RNA Technology Universe." Read the full article here:

July 14, 2023 Immunomic Therapeutics is highlighted in Washington Business Journal's cover story, “Life sciences funding is tough, but there are still avenues to money.” WBJ talks about how a

March 06, 2023 09:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that

January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that

Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time   GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a company that engineers precision delivery systems that overcome